Squarepoint
GPCR icon

Squarepoint’s Structure Therapeutics GPCR Stock Holding History

Squarepoint’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.74M Buy
125,575
+102,929
+455% +$4.55M 0.01% 1360
2026
Q1 		$1.09M Buy
+22,646
New +$1.55M ﹤0.01% 2706
2025
Q3 		– Sell
-15,176
Closed -$315K – 4592
2025
Q2 		$315K Buy
+15,176
New +$334K ﹤0.01% 3645
2024
Q4 		– Sell
-5,163
Closed -$227K – 5194
2024
Q3 		$227K Sell
5,163
-9,286
-64% -$359K ﹤0.01% 3616
2024
Q2 		$567K Buy
14,449
+617
+4% +$25.3K ﹤0.01% 2984
2024
Q1 		$593K Buy
+13,832
New +$583K ﹤0.01% 2935

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Squarepoint's GPCR Position: Q2 2026 in Review

Squarepoint increased its Structure Therapeutics (GPCR) stake by 455% in Q2 2026, buying an estimated $4.55M and bringing the position to 125,575 shares worth $6.74M. The position accounts for 0.01% of the portfolio, ranked #1360.

Squarepoint first reported a position in GPCR in Q1 2024 and has held it in 6 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Squarepoint held 125,575 shares of Structure Therapeutics worth $6.74M as of Q2 2026.
  • Squarepoint bought 102,929 Structure Therapeutics shares in Q2 2026, an estimated $4.55M.
  • Structure Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1360 holding.
  • Squarepoint first reported a position in Structure Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.